Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$151.43
-4.43-2.84%
At close: -
$151.43
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Ascendis Pharma Analyst Ratings and Price Targets | NASDAQ:ASND | Benzinga
Ascendis Pharma AS has a consensus price target of $190.76 based on the ratings of 17 analysts. The high is $289 issued by Wells Fargo on September 17, 2024. The low is $89 issued by Credit Suisse on June 14, 2023. The 3 most-recent analyst ratings were released by JP Morgan, Cantor Fitzgerald, and Evercore ISI Group on March 18, 2025, February 25, 2025, and February 18, 2025, respectively. With an average price target of $220 between JP Morgan, Cantor Fitzgerald, and Evercore ISI Group, there's an implied 45.28% upside for Ascendis Pharma AS from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Cantor Fitzgerald
Evercore ISI Group
Goldman Sachs
UBS
1calculated from analyst ratings
Analyst Ratings for Ascendis Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | 32.07% | JP Morgan | Jessica Fye67% | $168 → $200 | Maintains | Overweight | Get Alert |
| 02/25/2025 | Buy Now | 32.07% | Cantor Fitzgerald | Li Watsek41% | $170 → $200 | Maintains | Overweight | Get Alert |
| 02/18/2025 | Buy Now | 71.7% | Evercore ISI Group | Josh Schimmer54% | $220 → $260 | Maintains | Outperform | Get Alert |
| 02/13/2025 | Buy Now | 48.58% | Goldman Sachs | Paul Choi57% | $200 → $225 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 10.94% | JP Morgan | Jessica Fye67% | $167 → $168 | Maintains | Overweight | Get Alert |
| 02/11/2025 | Buy Now | 12.26% | Cantor Fitzgerald | Li Watsek41% | $170 → $170 | Reiterates | Overweight → Overweight | Get Alert |
| 01/29/2025 | Buy Now | 10.28% | JP Morgan | Jessica Fye67% | $165 → $167 | Maintains | Overweight | Get Alert |
| 01/07/2025 | Buy Now | 29.43% | UBS | Eliana Merle46% | → $196 | Initiates | → Buy | Get Alert |
| 11/15/2024 | Buy Now | 1.04% | TD Cowen | Yaron Werber35% | $160 → $153 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | 19.53% | Wedbush | Andreas Argyrides69% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 11/15/2024 | Buy Now | 18.87% | Oppenheimer | Leland Gershell70% | $190 → $180 | Maintains | Outperform | Get Alert |
| 11/15/2024 | Buy Now | 12.26% | Cantor Fitzgerald | Li Watsek41% | $170 → $170 | Reiterates | Overweight → Overweight | Get Alert |
| 11/15/2024 | Buy Now | 36.7% | Stifel | Alex Thompson44% | $200 → $207 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | 12.26% | Cantor Fitzgerald | Li Watsek41% | $170 → $170 | Reiterates | Overweight → Overweight | Get Alert |
| 10/23/2024 | Buy Now | 14.9% | JP Morgan | Jessica Fye67% | $180 → $174 | Maintains | Overweight | Get Alert |
| 10/21/2024 | Buy Now | 5.66% | TD Cowen | Yaron Werber35% | $157 → $160 | Maintains | Buy | Get Alert |
| 09/23/2024 | Buy Now | 26.13% | B of A Securities | Tazeen Ahmad55% | $175 → $191 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 90.85% | Wells Fargo | Derek Archila58% | $264 → $289 | Maintains | Overweight | Get Alert |
| 09/17/2024 | Buy Now | 36.7% | Citigroup | David Lebowitz51% | $178 → $207 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 35.38% | Evercore ISI Group | Josh Schimmer54% | $191 → $205 | Maintains | Outperform | Get Alert |
| 09/17/2024 | Buy Now | 25.47% | Oppenheimer | Leland Gershell70% | $180 → $190 | Reiterates | Outperform → Outperform | Get Alert |
| 09/17/2024 | Buy Now | 32.07% | Goldman Sachs | Paul Choi57% | $180 → $200 | Maintains | Buy | Get Alert |
| 09/16/2024 | Buy Now | 12.26% | Cantor Fitzgerald | Li Watsek41% | $170 → $170 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 12.26% | Cantor Fitzgerald | Li Watsek41% | $170 → $170 | Reiterates | Overweight → Overweight | Get Alert |
| 09/05/2024 | Buy Now | 18.87% | Oppenheimer | Leland Gershell70% | → $180 | Upgrade | Perform → Outperform | Get Alert |
| 09/04/2024 | Buy Now | 17.55% | Citigroup | David Lebowitz51% | $193 → $178 | Maintains | Buy | Get Alert |
| 09/04/2024 | Buy Now | 8.96% | JP Morgan | Jessica Fye67% | $174 → $165 | Maintains | Overweight | Get Alert |
| 09/04/2024 | Buy Now | 3.68% | TD Cowen | Yaron Werber35% | $175 → $157 | Maintains | Buy | Get Alert |
| 09/04/2024 | Buy Now | 15.56% | B of A Securities | Tazeen Ahmad55% | $165 → $175 | Maintains | Buy | Get Alert |
| 09/04/2024 | Buy Now | 74.34% | Wells Fargo | Derek Archila58% | $277 → $264 | Maintains | Overweight | Get Alert |
| 09/04/2024 | Buy Now | 12.26% | Cantor Fitzgerald | Li Watsek41% | $173 → $170 | Maintains | Overweight | Get Alert |
| 08/21/2024 | Buy Now | 14.9% | JP Morgan | Jessica Fye67% | $170 → $174 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 29.43% | Jefferies | Kelly Shi40% | $174 → $196 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 28.77% | Goldman Sachs | Paul Choi57% | $170 → $195 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 15.56% | TD Cowen | Yaron Werber35% | $156 → $175 | Upgrade | Hold → Buy | Get Alert |
| 05/31/2024 | Buy Now | 32.07% | Stifel | Alex Thompson44% | → $200 | Initiates | → Buy | Get Alert |
| 05/16/2024 | Buy Now | -7.55% | Morgan Stanley | Vikram Purohit38% | $116 → $140 | Maintains | Equal-Weight | Get Alert |
| 05/15/2024 | Buy Now | 14.24% | Cantor Fitzgerald | Li Watsek41% | $173 → $173 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2024 | Buy Now | 73.02% | Wells Fargo | Derek Archila58% | $260 → $262 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | 12.26% | JP Morgan | Jessica Fye67% | $167 → $170 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | 14.24% | Cantor Fitzgerald | Li Watsek41% | → $173 | Reiterates | Overweight → Overweight | Get Alert |
| 04/22/2024 | Buy Now | -23.4% | Morgan Stanley | Vikram Purohit38% | $116 → $116 | Maintains | Equal-Weight | Get Alert |
| 04/18/2024 | Buy Now | 14.24% | Cantor Fitzgerald | Li Watsek41% | $173 → $173 | Reiterates | Overweight → Overweight | Get Alert |
| 04/02/2024 | Buy Now | 10.28% | JP Morgan | Jessica Fye67% | $165 → $167 | Maintains | Overweight | Get Alert |
| 04/01/2024 | Buy Now | 14.24% | Cantor Fitzgerald | Li Watsek41% | $173 → $173 | Reiterates | Overweight → Overweight | Get Alert |
| 03/15/2024 | Buy Now | 71.7% | Wells Fargo | Derek Archila58% | $196 → $260 | Maintains | Overweight | Get Alert |
| 02/08/2024 | Buy Now | 20.19% | Citigroup | David Lebowitz51% | $146 → $182 | Maintains | Buy | Get Alert |
| 02/08/2024 | Buy Now | 48.58% | Wedbush | Andreas Argyrides69% | $207 → $225 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | 14.24% | Cantor Fitzgerald | Li Watsek41% | $152 → $173 | Maintains | Overweight | Get Alert |
| 12/20/2023 | Buy Now | 33.39% | Wedbush | Andreas Argyrides69% | $200 → $202 | Maintains | Outperform | Get Alert |
| 12/20/2023 | Buy Now | 0.38% | Cantor Fitzgerald | Li Watsek41% | → $152 | Reiterates | Overweight → Overweight | Get Alert |
| 12/20/2023 | Buy Now | -0.94% | Jefferies | Kelly Shi40% | → $150 | Initiates | → Buy | Get Alert |
| 12/19/2023 | Buy Now | -1.6% | Wells Fargo | Derek Archila58% | $137 → $149 | Maintains | Overweight | Get Alert |
| 11/09/2023 | Buy Now | -23.4% | Morgan Stanley | Vikram Purohit38% | $113 → $116 | Maintains | Equal-Weight | Get Alert |
| 11/08/2023 | Buy Now | 26.79% | Wedbush | Andreas Argyrides69% | → $192 | Reiterates | Outperform → Outperform | Get Alert |
| 09/15/2023 | Buy Now | 0.38% | Cantor Fitzgerald | Li Watsek41% | → $152 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | Buy Now | 0.38% | Cantor Fitzgerald | Li Watsek41% | → $152 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2023 | Buy Now | -11.51% | Wells Fargo | Derek Archila58% | $139 → $134 | Maintains | Overweight | Get Alert |
| 09/06/2023 | Buy Now | 26.79% | Wedbush | Andreas Argyrides69% | $187 → $192 | Maintains | Outperform | Get Alert |
| 09/06/2023 | Buy Now | -25.38% | Morgan Stanley | Vikram Purohit38% | $109 → $113 | Maintains | Equal-Weight | Get Alert |
| 08/07/2023 | Buy Now | -28.02% | Morgan Stanley | Vikram Purohit38% | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/01/2023 | Buy Now | -28.02% | Morgan Stanley | Vikram Purohit38% | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/31/2023 | Buy Now | -28.02% | Morgan Stanley | Vikram Purohit38% | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/24/2023 | Buy Now | -28.02% | Morgan Stanley | Vikram Purohit38% | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/17/2023 | Buy Now | -28.02% | Morgan Stanley | Vikram Purohit38% | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/26/2023 | Buy Now | -28.02% | Morgan Stanley | Vikram Purohit38% | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/20/2023 | Buy Now | -28.02% | Morgan Stanley | Vikram Purohit38% | → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/14/2023 | Buy Now | -41.23% | Credit Suisse | Tiago Fauth41% | → $89 | Assumes | → Neutral | Get Alert |
| 06/12/2023 | Buy Now | -28.02% | Morgan Stanley | Vikram Purohit38% | → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/07/2023 | Buy Now | 23.49% | Wedbush | Andreas Argyrides69% | → $187 | Reiterates | Outperform → Outperform | Get Alert |
| 06/02/2023 | Buy Now | 23.49% | Wedbush | Andreas Argyrides69% | $186 → $187 | Maintains | Outperform | Get Alert |
| 06/01/2023 | Buy Now | 0.38% | Cantor Fitzgerald | Li Watsek41% | → $152 | Reiterates | Overweight → Overweight | Get Alert |
| 05/08/2023 | Buy Now | 22.83% | Wedbush | Andreas Argyrides69% | $195 → $186 | Maintains | Outperform | Get Alert |
| 04/28/2023 | Buy Now | 0.38% | Cantor Fitzgerald | Li Watsek41% | $142 → $152 | Maintains | Overweight | Get Alert |
| 04/28/2023 | Buy Now | -28.02% | Morgan Stanley | Vikram Purohit38% | $107 → $109 | Maintains | Equal-Weight | Get Alert |
| 04/28/2023 | Buy Now | -41.23% | Credit Suisse | Tiago Fauth41% | $82 → $89 | Maintains | Neutral | Get Alert |
| 04/05/2023 | Buy Now | -3.59% | Citigroup | David Lebowitz51% | $163 → $146 | Maintains | Buy | Get Alert |
| 04/05/2023 | Buy Now | — | Oppenheimer | Leland Gershell70% | — | Downgrade | Outperform → Perform | Get Alert |
| 04/04/2023 | Buy Now | -28.68% | Morgan Stanley | Vikram Purohit38% | $151 → $108 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/04/2023 | Buy Now | -39.25% | B of A Securities | Tazeen Ahmad55% | $132 → $92 | Maintains | Buy | Get Alert |
| 04/03/2023 | Buy Now | — | Credit Suisse | Tiago Fauth41% | — | Downgrade | Outperform → Neutral | Get Alert |
| 02/17/2023 | Buy Now | -0.28% | Morgan Stanley | Vikram Purohit38% | $148 → $151 | Maintains | Overweight | Get Alert |
| 02/17/2023 | Buy Now | -14.15% | Credit Suisse | Tiago Fauth41% | → $130 | Reiterates | → Outperform | Get Alert |
| 01/17/2023 | Buy Now | 7.64% | SVB Leerink | Joseph Schwartz50% | $148 → $163 | Maintains | Outperform | Get Alert |
| 01/03/2023 | Buy Now | 16.89% | Wells Fargo | Derek Archila58% | $169 → $177 | Maintains | Overweight | Get Alert |
| 11/15/2022 | Buy Now | -2.27% | Morgan Stanley | Vikram Purohit38% | $146 → $148 | Maintains | Overweight | Get Alert |
| 11/14/2022 | Buy Now | -2.27% | SVB Leerink | Joseph Schwartz50% | $168 → $148 | Maintains | Outperform | Get Alert |
| 11/14/2022 | Buy Now | 8.3% | Wedbush | Andreas Argyrides69% | $151 → $164 | Maintains | Outperform | Get Alert |
| 11/07/2022 | Buy Now | 11.6% | Wells Fargo | Derek Archila58% | $172 → $169 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | -14.15% | Credit Suisse | Tiago Fauth41% | $123 → $130 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | -3.59% | Morgan Stanley | Vikram Purohit38% | $148 → $146 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 7.64% | Citigroup | David Lebowitz51% | $157 → $163 | Maintains | Buy | Get Alert |
| 10/20/2022 | Buy Now | 14.9% | Goldman Sachs | Paul Choi57% | → $174 | Initiates | → Buy | Get Alert |
| 09/22/2022 | Buy Now | 13.58% | Wells Fargo | Derek Archila58% | $167 → $172 | Maintains | Overweight | Get Alert |
| 08/30/2022 | Buy Now | 9.62% | Berenberg | Caroline Palomeque60% | → $166 | Assumes | → Buy | Get Alert |
| 08/11/2022 | Buy Now | -2.27% | Morgan Stanley | Vikram Purohit38% | $152 → $148 | Maintains | Overweight | Get Alert |
| 08/11/2022 | Buy Now | -4.91% | Oppenheimer | Leland Gershell70% | $154 → $144 | Maintains | Outperform | Get Alert |
| 08/11/2022 | Buy Now | 10.94% | SVB Leerink | Joseph Schwartz50% | $174 → $168 | Maintains | Outperform | Get Alert |
| 05/12/2022 | Buy Now | -18.77% | Credit Suisse | Tiago Fauth41% | $194 → $123 | Maintains | Outperform | Get Alert |
| 05/12/2022 | Buy Now | 4.34% | Citigroup | David Lebowitz51% | $187 → $158 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Ascendis Pharma (ASND) stock?
The latest price target for Ascendis Pharma (NASDAQ:ASND) was reported by JP Morgan on March 18, 2025. The analyst firm set a price target for $200.00 expecting ASND to rise to within 12 months (a possible 32.07% upside). 44 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ascendis Pharma (ASND)?
The latest analyst rating for Ascendis Pharma (NASDAQ:ASND) was provided by JP Morgan, and Ascendis Pharma maintained their overweight rating.
When was the last upgrade for Ascendis Pharma (ASND)?
The last upgrade for Ascendis Pharma AS happened on September 5, 2024 when Oppenheimer raised their price target to $180. Oppenheimer previously had a perform for Ascendis Pharma AS.
When was the last downgrade for Ascendis Pharma (ASND)?
The last downgrade for Ascendis Pharma AS happened on April 5, 2023 when Oppenheimer changed their price target from N/A to N/A for Ascendis Pharma AS.
When is the next analyst rating going to be posted or updated for Ascendis Pharma (ASND)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ascendis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ascendis Pharma was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating Ascendis Pharma (ASND) correct?
While ratings are subjective and will change, the latest Ascendis Pharma (ASND) rating was a maintained with a price target of $168.00 to $200.00. The current price Ascendis Pharma (ASND) is trading at is $151.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.